LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! This week has been a bit of a whirlwind, I’ve been working on my own research project. But we do have some interesting studies and a promising update!Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. For more details on everything I talk about here, you can always visit ProstateWarriors.com.​

Clinical Research

• CELC-G-201: Targeting mCRPC with Dual Inhibition​
  CELC-G-201 is a Phase 1/1b/2 clinical trial investigating a treatment strategy for men with metastatic castration-resistant prostate cancer (mCRPC). It combines gedatolisib, which inhibits the PI3K/AKT/mTOR pathway, with darolutamide, a proven androgen receptor inhibitor. The trial has enrolled 38 patients so far, aiming for 46 more in Phase 1 and approximately 30 in Phase 2. Early results from Phase 1 are promising, with a 6-month radiographic progression-free survival rate of 66%, and no patients have required dose reductions or discontinued due to side effects.
  ​
• MEVPRO-3: Enhancing Enzalutamide for mCSPC​
  MEVPRO-3 is a Phase 3 clinical trial preparing to enroll around 900 men globally to test whether combining Mevrometostat (PF-06821497) with Enzalutamide outperforms Enzalutamide alone in patients with metastatic castration-sensitive prostate cancer (mCSPC) who haven’t received previous androgen receptor pathway inhibitors (ARPIs). Mevrometostat is a selective EZH2 inhibitor that may delay resistance to hormone therapy and suppress cancer growth. Earlier studies in mCRPC showed the combination extended median rPFS to 14.3 months versus 6.2 months with Enzalutamide alone, with side effects reported as manageable.

Preclinical Research

• All-in-One Cancer Nanomedicine from KRISS​
  Researchers at the Korea Research Institute of Standards and Science (KRISS) have developed gold-iron-gold nanodisks (AuFeAuNDs), a multifunctional nanomedicine that integrates cancer imaging, therapy, and immune response stimulation. These trilayer nanodisks consist of a central iron core flanked by gold layers. They provide real-time tumor imaging through photoacoustic techniques, deliver photothermal and chemodynamic therapies, and trigger ferroptosis—a form of programmed cell death. Furthermore, they enhance immune activation by releasing damage-associated molecular patterns, which boost cytotoxic T-cell activity and increase immune cell numbers up to threefold. Although still in the pre-clinical stage, studies in tumor-bearing mice have shown very promising results across all functions, pointing to significant potential in reducing cancer recurrence.
  ​
• MDNA113: A Targeted Immunotherapy on the Horizon​
  MDNA113 is a first-in-class immunotherapy that targets aggressive prostate cancers and other difficult tumors. It fuses an anti-PD1 antibody with an IL-2 Superkine to both block the tumor’s immune evasion and supercharge the body’s immune response. MDNA113 specifically targets IL-13Rα2, a receptor often overexpressed in castration-resistant prostate cancer. The therapy is “masked” and only activated in the tumor microenvironment, reducing systemic toxicity. Preclinical data show that MDNA113 accumulates in IL-13Rα2-rich tumors and stimulates strong immune responses in cancers typically resistant to immunotherapy.​
  ​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max